https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-04 / Cancer Immunol. Immunother. 2020 Jul;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-04 / Cancer Immunol. Immunother. 2020 Jul;2020-07-04 00:00:002020-07-04 00:00:00Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-06-20 / Oncotarget 2017 Jun;8(25):41538-41548
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-06-20 / Oncotarget 2017 Jun;8(25):41538-415482017-06-20 00:00:002019-02-15 08:51:22A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-01-27 / Crit. Rev. Oncol. Hematol. 2017 Mar;111:87-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-01-27 / Crit. Rev. Oncol. Hematol. 2017 Mar;111:87-932017-01-27 00:00:002019-02-15 08:51:20Immunotherapy for the treatment of multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-01-06 / Pharmacotherapy 2017 01;37(1):129-143
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-01-06 / Pharmacotherapy 2017 01;37(1):129-1432017-01-06 00:00:002019-02-15 08:51:21Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-01-01 / Curr Cancer Drug Targets 2017;17(9):782-805
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-01-01 / Curr Cancer Drug Targets 2017;17(9):782-8052017-01-01 00:00:002019-02-15 08:36:11Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-11-23 / Exp. Hematol. 2017 Feb;46:48-55
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-11-23 / Exp. Hematol. 2017 Feb;46:48-552016-11-23 00:00:002019-02-15 08:51:22Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-11-14 / Bone Marrow Transplant. 2017 Feb;52(2):228-237
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-11-14 / Bone Marrow Transplant. 2017 Feb;52(2):228-2372016-11-14 00:00:002019-02-15 08:51:19Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-10-01 / J. Immunother. 2015 Oct;38(8):330-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-10-01 / J. Immunother. 2015 Oct;38(8):330-92015-10-01 00:00:002019-02-15 08:51:17Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-18 / Crit. Rev. Oncol. Hematol. 2015 Nov;96(2):339-54
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-18 / Crit. Rev. Oncol. Hematol. 2015 Nov;96(2):339-542015-06-18 00:00:002019-02-15 08:51:18Vaccination of multiple myeloma: Current strategies and future prospects
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-04-14 / Chonnam Med J 2015 Apr;51(1):1-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-04-14 / Chonnam Med J 2015 Apr;51(1):1-72015-04-14 00:00:002019-02-15 08:51:23Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic
